We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nodality Announces Publication of Promising Data in Melanoma in JTM
Product News

Nodality Announces Publication of Promising Data in Melanoma in JTM

Nodality Announces Publication of Promising Data in Melanoma in JTM
Product News

Nodality Announces Publication of Promising Data in Melanoma in JTM


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Nodality Announces Publication of Promising Data in Melanoma in JTM"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nodality, Inc. has announced promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Nodality's SCNP technology reveals functional biology underlying the most important and intractable diseases, providing critical insights to help guide the discovery and development of next-generation therapeutic agents.

According to data published in the current issue of the Journal of Translational Medicine (JTM), Nodality's researchers have identified key biomarkers in the blood that can help predict responses to new therapies for melanoma, including cancer immunotherapeutics.

“While there has been exciting recent progress in the treatment of melanoma, new therapies have been found to benefit only a subset of patients and are often associated with significant adverse effects,” commented Laura Brege, Nodality's President and Chief Executive Officer.

Brege continued, “With our highly sensitive and reproducible SCNP platform, we are able to attain a deep, functional understanding of how the immune system behaves in the presence of tumor cells and how cancer cells vary in their response to approved and promising development-stage therapies. In light of SCNP's broad range of capabilities and potential applications, we believe our technology can play an essential role in advancing pipelines of targets and therapeutics to deliver the next generation of drugs for cancer and other major illnesses.”

For access to the JTM article, titled “Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification,” please visit http://www.translational-medicine.com/content/12/S1/O13.

Advertisement